Detection of MSI in Circulating Tumor DNA of Colorectal Carcinoma Patients
Launched by UNIVERSITY OF SOUTHERN CALIFORNIA · Jul 11, 2018
Trial Information
Current as of June 12, 2025
Terminated
Keywords
ClinConnect Summary
PRIMARY OBJECTIVES:
I. To test the hypothesis that there is high level of concordance between the electrophoretic mobility profile of microsatellite biomarkers in circulating cell-free deoxyribonucleic acid (ccfDNA) versus in primary tumor tissues in patients with colorectal carcinomas displaying microsatellite instability.
II. To test the hypothesis that changes in the electrophoretic mobility profile of microsatellite biomarkers in liquid biopsies from patients with colorectal carcinoma correlate with therapeutic responsiveness measured based on Response Evaluation Criteria in Solid Tum...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients newly diagnosed with stage IV colorectal cancer and with defined microsatellite instability status before initiation of systemic immunotherapy.
- • Trackable cancer-driver mutation in the primary tumor documented before initiation of chemotherapy.
- • Zubrod performance status of 0 or 1.
- • Patients have measurable disease according to RECIST version (v)1.1.
- • Ability to understand and willing to sign a written informed consent.
- Exclusion Criteria:
- • Severe anemia (hemoglobin \[Hb\] \< 8 g/dL).
About University Of Southern California
The University of Southern California (USC) is a prestigious research institution located in Los Angeles, California, known for its commitment to advancing knowledge and innovation in various fields, including medicine and health sciences. As a clinical trial sponsor, USC leverages its extensive resources, interdisciplinary expertise, and state-of-the-art facilities to conduct cutting-edge research aimed at improving patient outcomes and public health. The university fosters collaboration among its diverse faculty and students, ensuring a dynamic environment for the development and implementation of clinical studies that adhere to the highest ethical and scientific standards. Through its clinical trials, USC aims to contribute to the advancement of medical science and the translation of research findings into practical applications that benefit communities locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Los Angeles, California, United States
Newport Beach, California, United States
Newport Beach, California, United States
Patients applied
Trial Officials
Heinz Josef Lenz, MD
Principal Investigator
University of Southern California
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials